Veracyte (VCYT) investor relations material

Business performance and growth

• Decipher grew 32% and Afirma 9% year-to-date in volume, with Decipher exceeding expectations and Afirma meeting them.

• Strong adjusted EBITDA performance and profitability, with 2025 off to an excellent start.

• Coverage for Decipher at 200 million lives and Afirma at 275 million, with ongoing efforts to close remaining gaps.

• No significant coverage gaps remain, with Medicaid as a minor gap for both core tests.

• Expectation to achieve ASP gains for Decipher over a five-year timeframe.

Product innovation and launches

• Launched Decipher metastatic product and internal V2 transcriptome product for lab efficiency and scalability.

• Completed enrollment of the 2,400-patient Nightingale study for MRD, advancing long-term growth drivers.

• GRID research tool and V2 transcriptome assay launched to support Afirma and future products.

• Prosigna U.S. launch targeted for early to mid-2026, aiming to provide incremental insights in breast cancer.

• MRD test launch expected in first half of 2026, starting with muscle invasive bladder cancer.

Market strategy and penetration

• Decipher holds 65% market share in prostate cancer, with strategies to increase penetration in metastatic and high-risk segments.

• NCCN guidelines and new evidence, such as Stampede, are key catalysts for further adoption.

• Afirma targets increasing penetration from 65% toward 80%, leveraging data and evidence generation.

• No significant expansion of sales force needed; current teams are effective and optimal.

• International strategy focuses on launching IVDs and obtaining country-by-country reimbursement.